Sort
50,496 grants matching “lung cancer”
National Lung Screening Trial (NLST)
$817,737Henry Ford Health System · N01 · FY2008 · CA
The Worcester Venous Thromboembolism Study
$817,624Frederick A Spencer · Univ Of Massachusetts Med Sch Worcester · R01 · FY2008 · HL
Clonal hematopoiesis and inherited genetic variation in sickle cell disease
$817,595Alexander Bick · Vanderbilt University Medical Center · R01 · FY2023 · HL
TRAINING IN LUNG SCIENCE
$817,524David H Ingbar · University Of Minnesota · T32 · FY2016 · HL
Solid Tumors
$817,433Lee J. Helman · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA
PRIMARY PRODUCT/SERVICE CODE TO: B537, DESCRIPTION: CENTRAL DATA COLLECTION CENTER (CDCC), WESTAT
$817,270Sunitha Mathew · Westat, Inc. · N01 · FY2020 · CA
Development of TIMP-2 derivatives or strategies as biologic therapies for cancer
$817,239William Stetler-Stevenson · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Strategies for Therapeutic Cancer Vaccine Clinical Trials
$816,925Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
CANCER AWARENESS NETWORK FOR IMMIGRANT MINORITY POPULATI
$816,913New York University School Of Medicine · U01 · FY2004 · CA
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism
$816,753Margaret C. Fang · University Of California, San Francisco · R01 · FY2010 · HL
Immune reconstitution following autologous and allogeneic stem cell transplant
$816,678Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
Cancer Risk in Human Populations
$816,676Debra Silverman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2010 · CA
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV disease
$816,613Sulggi Angela Lee · University Of California, San Francisco · R01 · FY2019 · AI
Autologous Lung Multipotent Stromal Cell Therapy for Emphysema
$816,611Edward P Ingenito · Brigham And Women'S Hospital · R01 · FY2015 · HL
Nutrition, Metabolism, and Cancer
$816,583Regina G Ziegler · Division Of Cancer Epidemiology And Genetics · ZIA · FY2014 · CA
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Statistics and Data Management Core
$816,560Janet Ellen Dancey · Queen'S University At Kingston · U10 · FY2020 · CA
Host factors, tumor microenvironment and survival in a multiethnic study of Hodgkin lymphoma patients
$816,487Wendy Cozen · University Of Southern California · R01 · FY2017 · CA
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
$816,402Elsa R Flores · H. Lee Moffitt Cancer Ctr & Res Inst · R35 · FY2016 · CA
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3
$816,289Elio Riboli · Imperial College Of Science, Technology And Medicine · U01 · FY2010 · CA
ATECAR: Asian Training, Education on Cancer & Research
$816,182Grace X Ma · Temple Univ Of The Commonwealth · U01 · FY2009 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
$815,928Song Yao · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA
Translational Studies of the Histone Deacetylase Inhibitor Romidepsin
$815,865Susan Bates · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Vascular, Pulmonary and Renal Injury
$815,633Richard N Mitchell · Brigham And Women'S Hospital · T32 · FY2016 · HL
Approaches To Immunological Intervention In Schistosomiasis
$815,605Thomas Wynn · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Development of a low dose clinical lung screening prototype for early detection of COPD and lung cancer using a novel x-ray source to enable Talbot-Lau interferometry
$815,604David Vine · Sigray, Inc. · R44 · FY2022 · HL